Home  »  Industry   »  Analysts suggest Aridis Pharmaceuticals Inc. (ARDS...

Analysts suggest Aridis Pharmaceuticals Inc. (ARDS) could spike 95.58% in a year

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) is -28.81% lower on its value in year-to-date trading and has touched a low of $0.68 and a high of $2.94 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARDS stock was last observed hovering at around $1.17 in the last trading session, with the day’s loss setting it -0.33% off its average median price target of $10.50 for the next 12 months. It is also 95.58% off the consensus price target high of $19.00 offered by 2 analysts, but current levels are 58.0% higher than the price target low of $2.00 for the same period.

Currently trading at $0.84, the stock is -31.28% and -19.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 9.93 million and changing -28.21% at the moment leaves the stock -33.06% off its SMA200. ARDS registered -47.50% loss for a year compared to 6-month loss of -26.96%.

5 Undervalued Stocks For 2023

Approximately 544 miles north of Las Vegas lies what's been dubbed "the biggest lithium deposit in the US." One tiny company stands to be the biggest beneficiary because lithium "faces a long-term supply shortage," according to Barron's. This company, however, is sitting on a goldmine opportunity as it plans to produce 30,000 tonnes per annum over the next 3.5 years from this single deposit. Supplying the electric vehicle boom and potentially driving its stock price off the charts. But this is just one of the opportunities we have researched in our free report. The other four companies have just as much potential.

Click here to download your Free Copy…


The stock witnessed a -18.45% gain in the last 1 month and extending the period to 3 months gives it a -16.00%, and is -35.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 45.12% over the week and 23.32% over the month.

Aridis Pharmaceuticals Inc. (ARDS) has around 34 employees, a market worth around $18.93M and $2.90M in sales. Distance from 52-week low is 23.08% and -71.43% from its 52-week high. The company has generated returns on investments over the last 12 months (591.40%).

Aridis Pharmaceuticals Inc. (ARDS) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Aridis Pharmaceuticals Inc. (ARDS) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 2.30, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Aridis Pharmaceuticals Inc. is expected to release its quarterly report on 05/16/2023.The EPS is expected to shrink by -54.70% this year.

Aridis Pharmaceuticals Inc. (ARDS) Top Institutional Holders

The shares outstanding are 17.70M, and float is at 17.60M with Short Float at 0.55%.

Aridis Pharmaceuticals Inc. (ARDS) Insider Activity

A total of 0 insider transactions have happened at Aridis Pharmaceuticals Inc. (ARDS) in the last six months, with sales accounting for 0 and purchases happening 0 times.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts